Seattle Genetics, Takeda's cancer drug meets main goal in trial
September 29, 2014 at 07:38 AM EDT
Sept 29 (Reuters) - Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.
